Introduction
Primary HIV infection (PHI) is characterized by high levels of viral replication followed by induction of HIV-specific CD4 and CD8 T cell immune responses . Studies have shown that the magnitude of those immune responses determines the subsequent course of [1 -4 ] infection . However, these responses are ineffective at eradicating the virus, and the chronic infection characterized by a gradual loss [5 -7 ] of CD4 T cells leads to AIDS without therapy in the majority of patients.
A relationship between T cell activation, CD4 T cell decline and clinical outcome has been shown in the chronic phase of the infection . Several clinical studies have also demonstrated that the virological and immunological events that occur during PHI are strongly [8 -11 ] predictive of disease progression , . These reports support the hypothesis that HIV causes CD4 T cell depletion as a consequence of [ However, the influence of Treg in HIV infection remains unclear . Treg can limit immune activation and viral replication but may [24 ] dampen poly-functional adaptive immune responses against viral antigens , . [23 25 -28 ] In the present study we investigated whether Treg cells could be detected in early phases of HIV infection. For this, a comparison of Treg frequency, phenotype and function in patients studied at early and chronic stages of HIV infection was undertaken. The effects of in vitro stimulation with HIV antigen of purified Treg from patients diagnosed at the primary HIV infection (PHI) were studied. In a clinical stand point we looked at the correlation between Treg frequency and CD4 T cell counts and plasma HIV RNA values at PHI. The impact of combined antiretroviral therapy initiation during PHI on Treg function was studied in a 24-months longitudinal follow up of subjects.
Patients and Methods
This is a prospective study conducted in two clinical sites in France. To be enrolled subjects must have had evidence of acute or recent HIV infection as defined by a negative or weakly reactive HIV antibody enzyme immunoassay with less than 3 bands on HIV Western Blot and detectable plasma HIV RNA. Subjects were offered to participate to this study before physician s decision of c-ART initiation ' based on usual criteria and physician s judgment. Chronic HIV-infected patients included in this study have received c-ART for at least ' one year and exhibited CD4 cell counts above 500 cells/mm and plasma HIV viral load below 50 copies/ml. Fresh blood samples were 3 collected on EDTA tubes and processed within 3 hours after they were drawn. All patients provided written informed consent; the study was approved by the ethical committee of H pital Europ en Georges Pompidou, Paris, France. CD4 CD25 cells were subsequently separated using 2 passages on magnetic columns. This generally resulted in obtaining higher than + high 85 purity of cell populations. Monocytes (> 90 purity) obtained by plastic adherence, were used as antigen-presenting cells.
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Flow cytometric analysis
Phenotyping of the CD4 CD25 and CD4 CD25 cell subsets was performed on fresh whole blood samples using four-colour direct
flow cytometry. Monoclonal antibodies (mAbs) conjugated to fluorescein isothiocyanate (FITC), phycoerythrin (PE), peridinin chlorophyl protein (PerCP) or allophycocyanin (APC) were used for immunostaining (All purchased by BD Biosciences; Le Pont Claix, France):
anti-CD25-FITC, anti-CD4-PerCP, anti-CD3-APC, anti-CD45RO-APC, anti-CD25-APC, anti-CD25-PE, anti-HLA-DR-PE, anti-CD45RA-PE, anti-CD127-PE, anti-CD40L-PE, anti-CD122-PE, anti-CD95-PE, anti-CD69-PE, anti-CD103-PE and anti-CTLA-4-PE as previously described . For staining of Foxp3, the cells were fixed and permeabilized using a fixation/permeabilization kit according [23 ] to the manufacturer s protocol. Lymphocytes were stained with Alexafluor 488 anti-human Foxp3 (PCH101, eBioscience, San Diego, CA).
'
Isotype-matched controls were used in all staining experiments. The production of IL-10 and IL-2 by anti-CD3/anti-CD28 or p24 activated CD4 CD25 and CD4 CD25 purified cells was assessed as previously described .
Analyses were performed using FACScalibur and CellQuest software (Becton Dickinson, San Jose, California, USA) on at least ™ ™ 10 000 events. Gating was restricted to the population of lymphocytes according to their light scattering properties.
Proliferation and suppression assays
The different subpopulations (CD4 CD25 cells and CD4 CD25 cells) were assessed for their proliferative capacities in response to
polyclonal stimulation and to recall antigens and p24 protein as previously described . Antigen tested were: 5 g/ml purified tuberculin calculated as follows: 1 (mean cpm of co-culture wells divided by mean cpm of CD4 CD25 cells cultured alone) 100. Cell
proliferation was assessed using 0.5 Ci H thymidine (Amersham Pharmacia, Uppsala, Sweden) incorporation. Stimulation indices were
calculated by dividing the mean cpm of stimulated cells by the mean cpm of unstimulated cells. 
RNA isolation and real time quantitative RT-PCR
Statistical analysis
Data are expressed as mean S.D for percentages and median and ranges for absolute values. Statistical comparisons were performed ± using Mann Whitney rank sum test. Analysis of correlation was assessed using the Spearman Rank Test for non parametric data. All results were conducted using Prism GraphPad Ver5 (Graphpad Software, San Digo, CA, USA). Significance was considered for value of P 0.05.
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Results
Phenotypic characteristic of circulating CD4 CD25
T cells in PHI patients
Seventeen patients diagnosed early after PHI (median: 13 days; 1 55 days) were studied. Median CD4 cell count was 480 cells/ L (33 -μ 1306) and plasma HIV RNA levels ranged between 3.3 to 5.7 log cp/mL. Since the level of immune activation in non-treated PHI -10 patients may hamper discrimination between Treg and activated CD4 T cells that may also express CD25 and FoxP3 molecules, we evaluated the percentages of cells expressing high levels of CD25. These cells exhibit lower levels of CD127 molecules and higher FoxP3 expression as compared to CD4 CD25 and CD4 CD25 T cells as shown in for a representative PHI patient. Figure 1A and B Analysis of the cohort of PHI and c-ART treated chronic patients (n 19) showed that the median percentages of CD4 CD25 T cells = + high were 2.2 and 5.3 in PHI and chronic patients, respectively (p<0.05) ( ).
% % Figure 1C We investigated whether these CD4 CD25 T cells might exhibit other phenotypic features of Treg previously characterized in
As shown in , analysis of CD4 CD25 from 13 PHI patients showed that these cells of CD4 CD25 compared to CD4 CD25 T cells express antigens like CD69 (20 ) (P<0.001), CD103 (17 ) (P<0.001) and iCTLA-4
(18 ) (P<0.05). We next confirmed that purified CD4 CD25 T cells isolated from PHI patients express high levels of FoxP3 CD25 to tuberculin and p24 protein in PHI (n 9) and chronic patients (n 6). At a ratio CD4 CD25 /CD4 CD25 of 1/4, CD4 CD25
from PHI and chronic patients inhibited by 37 and 46 in median autologous CD4 CD25 proliferation to PPD, respectively. At the
same ratio, the response to p24 antigens was inhibited by 50 and 52 by CD4 CD25 purified from PHI and chronic patients,
respectively ( ). This suppressive effect was up to 75 when cells were mixed at a 1/1 ratio. figure 2B 
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Analysis of cytokine expression by CD4 CD25
T cells from PHI patients in response to HIV antigens
We have previously demonstrated that Treg isolated from chronic patients treated with cART exhibited a specific bias towards HIV antigens by producing either IL-10 or expressing TGF-transcripts . Therefore, we were interested to investigate whether such cells
could be detected among PHI patients. We have focused our analysis on purified CD4 CD25 T cells from 6 patients at early time after
Following polyclonal stimulation, the mean frequency of CD4 CD25 and CD4 CD25 T cells producing IL-2 increases
significantly from 2.3 / 0.65 and 0.6 / 0.06 to 15.5 / 4.1 and 7.8 / 1 , respectively ( ). In the same conditions, Figure 3A mean percentages of CD4 CD25 and CD4 CD25 producing IL-10 increased from 3.4 / 0.6 and 1.9 / 0.4 to 22.3 / 5.8 
the presence of p24 specific T cells producing IL-2 and IL-10 among CD4 CD25 isolated from PHI patients. at diagnosis (month 0) to 47 11.2 at month 24 (P NS). In contrast, suppressive activity of CD4 CD25 in response to p24
decreased from 59 8.2 at diagnosis to 27.4 5.8 at month 6 (P<0.05) and remained stable thereafter (23 10 at month 24) ( figure 5C with a higher CD4 T cell counts in PHI patients at diagnosis.
Discussion
The purpose of this study was to determine whether HIV-specific Treg are present at early stages of HIV infection and to characterize their suppressive activity in regard to CD4 HIV specific activity. We present data supporting the induction of HIV-specific Treg mediated suppression of HIV-specific CD4 T cells in PHI patients. Treg exhibiting a CD4 CD25 CD127 phenotype and expressing high levels Treg from PHI patients with HIV antigens led to an increase of IL-10 synthesis demonstrating the presence of a proportion of HIV specific T cells among Treg. Altogether, these data extended those previously reported in chronic patients demonstrating that HIV drives an [23 ] expansion of Treg since the PHI stage.
Human CD4 CD25 T cells have been shown to be a heterogeneous population that includes suppressive Treg cells, anergic but not
suppressive T cells and normal activated T cells . Interestingly, all these populations were detectable in PHI patients studied here.
[29 ]
Although no specific markers have been described for characterization of human Treg, the expression of high levels of CD25 and low density of CD127 molecules has been correlated with immunosuppressive Treg activity in humans . Using this combination of [30 ] markers and high expression of FoxP3 we attempted to quantify Treg in PHI patients. Although FoxP3 is now widely used for the characterization of human Treg cells in healthy individuals contrasting findings have been reported on the kinetics and functional T cell proliferation, a characteristic that was limited to CD4 CD25 CD127 T cells expressing higher levels of FoxP3. Thus, our
results demonstrate that a true population of Treg may be identified at the early stages of PHI.
The most effective method for assessing suppressive activity of Treg is to determine their capacity to suppress the proliferation of stimulated CD4 CD25 T cells. We show that Treg from PHI patients suppress HIV specific and non-specific proliferation of CD4 T + − cells. Interestingly, we found that the percentages of Treg in PHI patients were significantly lower than that observed in chronic patients.
However, it is possible that peripheral blood may not be the most appropriate compartment to accurately assess HIV-specific Treg cell activity, particularly at the time of primary infection. Several studies in chronically HIV-infected patients and non-human primate models We found a decrease in frequency of HIV, but not PPD, suppressive activity of Treg throughout a 24-months follow up of PHI patients who remained untreated. This also suggests a preferential homing of these cells to secondary lymphoid. Moreover, since Treg need to be activated through their TCR for exhibiting a suppressive activity these data reinforce the demonstration of the presence of shown that these cells are not preferentially infected by HIV , one hypothesis could be that Treg are infected and depleted in [41 ] non-treated PHI patients. Persistent antigens such as HIV are believed to promote the expansion and activation of antigen-specific Treg. In addition, we may speculate that, as recently reported, antigen presentation of HIV antigens by dendritic cells with tolerogenic properties and upregulation of inhibitory molecules might also participate to expansion of Treg in the context of PHI . The high levels of viral replication and [43 ] immune activation during PHI increase interactions between HIV or envelope proteins and CD4 or HIV-co-receptors, and may favor the peripheral conversion of memory activated CD4 T cells into Treg . Likely, this is suggested by the persistent capacity of Treg from 
Figure 5
Correlation between the frequency and activity of CD4 CD25 T cells and absolute CD4 cell counts in PHI patients
The correlations at diagnosis between total number of CD4 CD25 T cells and CD4 cell counts or plasma HIV RNA values (A), expression + high of activation marker HLA-DR on CD4 T cells (B) inhibition of CD4 CD25 proliferation in the presence of p24 and tuberculin (C) were + − investigated using a Spearman rank correlation coefficient test.
